Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Bristol Eyes 2008 NDA For DPP-4 Inhibitor Saxagliptin

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Firm also brokers licensing agreement with Otsuka for the diabetes candidate in Japan.

You may also be interested in...



Bristol-Myers Squibb Targets Mid-year Filing For Saxagliptin

Bristol and AstraZeneca reveal Onglyza brand name, positive monotherapy data for the DPP-4 inhibitor at American Diabetes Association meeting.

Bristol-Myers Squibb Targets Mid-year Filing For Saxagliptin

Bristol and AstraZeneca reveal Onglyza brand name, positive monotherapy data for the DPP-4 inhibitor at American Diabetes Association meeting.

Industry Eyes DPP-4, GLP-1 Data From Diabetes Meeting

BMS to release first Phase III data on saxagliptin as monotherapy.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

New EU Filings

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

See All
UsernamePublicRestriction

Register

PS063602

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By